Abu Dhabi

Abu Dhabi runs its own healthcare licensing and payment regime, and advice built for Dubai does not transfer here.

Healthcare in Abu Dhabi answers to the Department of Health (DOH), not the Dubai Health Authority, and the two regulators license and pay for care on separate terms. Since November 2025, day-case procedures are paid on an IR-DRG basis, which moves margin from the fee line to coding accuracy and theatre throughput. A roughly AED 55 billion PPP programme is also bringing health assets to market through 2026 and 2027. None of this is optional background for anyone active in Abu Dhabi's healthcare market.

Who engages this

Operators with facilities in Abu Dhabi, investors acquiring DOH-licensed hospitals, clinics, medical centres, or pharmacies, international groups deciding between Dubai and Abu Dhabi for market entry, and sponsors bidding into the emirate's PPP pipeline.

The work

What this practice takes on.

01

DOH Facility Licensing

Facility and personnel licensing sequenced before you sign a lease, with connectivity clearance built into the same timeline.

02

Day-Case DRG & Coding Economics

IR-DRG now prices day-case procedures by episode; margin moves to coding accuracy and theatre throughput, not the fee schedule.

03

Clinical Costing Compliance

DOH's costing standard expects patient-level cost that reconciles your ERP to your EMR, and most mid-size groups cannot produce it today.

04

PPP Bid Advisory

Feasibility work and a lender-grade model built ahead of tender, for sponsors chasing the emirate's health-infrastructure pipeline.

05

M&A Diligence on DOH-Licensed Assets

Change-of-control approval and licence transferability priced into the deal before the SPA, with payer concentration tested the same way.

06

Market Entry Structuring

ADGM or mainland, decided against your banking needs and the DOH licensing path each route implies.

07

Clinical AI Governance

DOH's Responsible AI Standard requires explainability and privacy controls, plus a named accountable owner, before you deploy.

08

Advanced-Therapy & Trial-Site Positioning

Positioning a facility as a qualified sponsor site against the ethics and biobanking standards global sponsors expect, with a pharmacovigilance record to match.

On a mandate

A mid-size Abu Dhabi hospital group asked us to review an acquisition target ahead of signing. The target's DOH facility licence carried an unresolved change-of-control condition from a prior transaction, and its day-case claims were coded two DRG weights above what the clinical notes supported, revenue that a payer audit could claw back. We priced both into the offer, resolved the licence condition ahead of signing, and the buyer closed eight weeks later at a valuation 14% below the original offer.

Questions

What clients ask first.

We hold a DHA licence in Dubai. Does it cover Abu Dhabi?

No. DOH licensing is a separate regime, with its own facility and personnel requirements and its own connectivity rules. Sequence the DOH application before you sign a lease or commit capital in the emirate, not after.

How does DOH's regime differ from DHA in practice?

DOH licenses and pays for care differently from DHA. Day-case procedures run on IR-DRG rather than fee-for-service, and clinical costing is moving toward patient-level reconciliation. Enforcement also runs on its own calendar, separate from DHA's. A DHA compliance programme does not map onto DOH's requirements line for line.

When should we position for the PPP pipeline?

Before the tender is issued. Feasibility work and a bankable financial model take months to build, and so do the sponsor relationships PPP evaluators expect. By the time a project is formally tendered, the sponsors who started early already hold the advantage.

We're evaluating an acquisition of a DOH-licensed facility. What should we check first?

Whether the change-of-control approval is achievable within your funding timeline, and whether day-case coding matches what the clinical documentation actually supports. Both are common places where an agreed price does not survive diligence.

If you operate in Abu Dhabi's healthcare market, or are weighing an investment or a PPP bid there, start with a conversation with a principal.

Engagement · Limited mandates

Choosing who advises you is itself a strategic decision.

We take a limited number of mandates at any time. If you are working a decision that needs independent counsel, start with a conversation.